US2017172985A1PendingUtilityA1

Veliparib in combination with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers

41
Assignee: ABBVIE INCPriority: Sep 16, 2014Filed: Mar 6, 2017Published: Jun 22, 2017
Est. expirySep 16, 2034(~8.1 yrs left)· nominal 20-yr term from priority
Inventors:Vincent L. GirandaGary B. GordonMark D. MckeeJane QianQin Qin
A61P 35/00A61P 43/00A61K 31/4188A61K 31/4184A61K 31/555A61K 31/282A61K 31/337A61P 11/00A61K 2300/00
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention pertains to a method for the treatment of non-small cell lung cancer in a subject who is a smoker, comprising administering to the subject an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (veliparib or ABT-888), or a pharmaceutically acceptable salt thereof, in combination with carboplatin and paclitaxel.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A method for the treatment of non-small cell lung cancer in a subject who is a smoker, comprising administering to the subject an effective amount of a PARP inhibitor in combination with standard of care for subjects with non-small cell lung cancer. 
     
     
         2 . The method of  claim 1 , wherein the smoker is a current smoker. 
     
     
         3 . The method of  claim 1 , wherein the smoker is a heavy smoker. 
     
     
         4 . The method of  claim 1 , wherein the smoker is a cotinine high patient. 
     
     
         5 . The method of  claim 1 , wherein the PARP inhibitor is 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method of  claim 1 , wherein the non-small cell lung cancer is squamous. 
     
     
         7 . The method of  claim 1 , wherein the non-small cell lung cancer is non-squamous. 
     
     
         8 . The method of  claim 1 , wherein the standard of care comprises platinum-based chemotherapy regimens. 
     
     
         9 . A method for the treatment of non-small cell lung cancer in a subject with the same DNA damage profile as that of a subject who is a smoker, comprising administering to the subject an effective amount of a PARP inhibitor in combination with standard of care for subjects with non-small cell lung cancer. 
     
     
         10 . The method of  claim 9 , wherein the smoker is a current smoker. 
     
     
         11 . The method of  claim 9 , wherein the smoker is a heavy smoker. 
     
     
         12 . The method of  claim 9 , wherein the smoker is a cotinine high patient. 
     
     
         13 . The method of  claim 9 , wherein the PARP inhibitor is 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof 
     
     
         14 . The method of  claim 9 , wherein the non-small cell lung cancer is squamous. 
     
     
         15 . The method of  claim 9 , wherein the non-small cell lung cancer is non-squamous. 
     
     
         16 . The method of  claim 9 , wherein the standard of care comprises platinum-based chemotherapy regimens. 
     
     
         17 . A composition comprising 2-[(2R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide, or a pharmaceutically acceptable salt thereof, for use in a method for the treatment of non-small cell lung cancer in a subject who is a smoker, or with a DNA damage profile similar to that of a subject who is a smoker. 
     
     
         18 . The composition of  claim 17 , wherein the smoker is a current smoker. 
     
     
         19 . The composition of  claim 17 , wherein the smoker is a heavy smoker. 
     
     
         20 . The composition of  claim 17 , wherein the smoker is a cotinine high patient. 
     
     
         21 . The composition of  claim 17 , additionally comprising, or additionally combined with, standard of care for subjects with non-small cell lung cancer. 
     
     
         22 . The composition of  claim 21 , wherein the standard of care comprises platinum-based chemotherapy regimens.

Join the waitlist — get patent alerts

Track US2017172985A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.